This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Acceleron Pharma, Inc.
Drug Names(s): HGT4510, HGT 4510, ActRIIB, ramatercept
Description: ACE-031 is a soluble fusion protein developed to inhibit myostatin and other negative regulators of muscle mass and strength. ACE-031 is based on the activin receptor type IIB (ActRIIB), which is the natural receptor for myostatin and other negative regulators of muscle mass. ACE-031 acts as a decoy receptor to bind GDF ligands before they are able to bind with ActRIIB on the surface of muscle cells. Binding to ACE-031 prevents signaling through ActRIIB receptors, thereby allowing normal muscle formation processes to occur.
Deal Structure: ACE-031 was originally developed by Acceleron Pharma.
In September 2010, Acceleron and Shire entered a joint development and commercialization agreement for ACE-031 and other molecules targeting the activin receptor type IIB pathway. Shire will receive an exclusive license to Accelerons ActRIIB molecules, including ACE-031, in markets outside of North America. Acceleron will retain all commercial rights in North America. Under the terms of the agreement, Shire will make an upfront cash payment to Acceleron of $45 million. Acceleron is eligible to receive additional development, regulatory and sales milestone payments of up to $165 million for ACE-031 in DMD, up to an additional $288 million for other indications and molecules, and royalty payments on product sales. Shire and Acceleron will share development costs in North America and Europe, and Shire will be responsible for development costs in other markets.
Abbvie and Shire
In July 2014, AbbVie and Shire...See full deal structure in Biomedtracker
Partners: Shire Pharmaceuticals Group PLC
Additional information available to subscribers only: